England’s NICE Not Planning To Include Societal & Genericization Factors In HTAs – For Now
Executive Summary
England’s NICE should factor in the impact of patent expiry on future drug prices when analyzing the cost effectiveness of new medicines and should also take account of societal benefits, a group of health economists has said.